drugset / Trial / NCT02013128
Ublituximab + Ibrutinib in Select B-cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Timeline
- Start
- 2014-01-06
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |